MULTIVITAMIN TABLETS

Indications

• Cancer (various types)
• Rheumatoid arthritis
• Multiple sclerosis
• Inflammatory bowel disease
• Psoriasis
• Hypercholesterolemia
• Infectious diseases (e.g., COVID-19)

Dosage

Children: Refer to the BNF for Children for paediatric dosing information, as it varies based on the specific monoclonal antibody and the condition being treated.

Adults: Refer to the specific monoclonal antibody product information for adult dosage, as it varies based on indication and specific agent used.

Mechanism of action

Monoclonal antibodies work by binding to specific proteins on the surface of cells. This binding can block the activity of certain proteins, mark cells for destruction by the immune system, or deliver cytotoxic agents directly to target cells. The mechanism of action varies depending on the specific monoclonal antibody but often involves modulation of immune response, inhibition of cell proliferation, and induction of apoptotic pathways.

Pharmacodynamics

The pharmacodynamics of monoclonal antibodies is primarily characterized by their specificity and affinity for targeted antigens. This leads to a variety of effects, including neutralization of pathogens, blockade of receptor-ligand interactions, and antibody-dependent cellular cytotoxicity. The clinical effects depend on the disease being treated and the specific antibody's action, such as inducing tumor regression in cancer or reducing inflammation in autoimmune diseases.

Pharmacokinetics

Monoclonal antibodies typically have a long half-life, allowing for less frequent dosing. They are generally administered intravenously or subcutaneously, with absorption and distribution influenced by the antibody's size and charge. The elimination occurs primarily through proteolytic degradation and intracellular recycling. Factors such as patient-specific variables, including immunogenicity and the presence of antibodies against the monoclonal antibody, can impact pharmacokinetics.

Interactions

• abatacept+monoclonalantibodies: Severe (increases risk of generalised infection (possibly life-threatening))
• anakinra+monoclonalantibodies: Severe (increases risk of generalised infection (possibly life-threatening))
• anthracyclines+monoclonalantibodies: Severe (increases risk of cardiotoxicity)
• filgotinib+monoclonalantibodies: Severe (increases risk of immunosuppression)
• monoclonalantibodies+fingolimod: Severe (increases risk of generalised infection (possibly life-threatening))
• normal immunoglobulin+monoclonalantibodies: Severe (affects effects)
• monoclonalantibodies+ozanimod: Severe (increases risk of generalised infection (possibly life-threatening))
• monoclonalantibodies+siponimod: Severe (increases risk of generalised infection (possibly life-threatening))
• monoclonalantibodies+vemurafenib: Severe (increases risk of hepatotoxicity)
• monoclonalantibodies+aminophylline: Moderate (decreases exposure)

Indications

• Angina pectoris
• Chronic stable angina
• Angina due to coronary artery disease

Dosage

Children: Refer to the appropriate prescribing guidelines and consult clinical references for paediatric dosing recommendations.

Adults: Refer to the appropriate prescribing guidelines and consult clinical references for specific adult dosing recommendations.

Mechanism of action

Isosorbide mononitrate is converted to nitric oxide (NO) in the body, which activates guanylate cyclase. This leads to an increase in cyclic guanosine monophosphate (cGMP) levels in smooth muscle cells, resulting in smooth muscle relaxation and vasodilation. This vasodilatory effect decreases preload and afterload on the heart, reducing myocardial oxygen demand and relieving symptoms of angina.

Pharmacodynamics

Mononitrate demonstrates a dose-dependent reduction in myocardial oxygen consumption by decreasing both venous return (preload) and systemic vascular resistance (afterload). It also facilitates coronary artery dilation, improving blood flow to ischemic myocardial tissue. The onset of action can be within 30 minutes, with peak effects generally occurring 1-2 hours after administration. The effects can last for 6-8 hours, depending on the dosing schedule.

Pharmacokinetics

Isosorbide mononitrate is well absorbed from the gastrointestinal tract, with a bioavailability of approximately 100% due to its oral formulation. It undergoes minimal first-pass metabolism. The peak plasma concentration is reached within 1-2 hours post-ingestion. The drug has a half-life of approximately 5 hours, and it is primarily eliminated via the kidneys as unchanged drug and metabolites. Steady-state concentrations are typically achieved within 24 hours of regular dosing.

Contra-indications

• Hypersensitivity to mononitrate or any of its components
• Severe hypotension
• Cardiogenic shock
• Severe anemia
• Concurrent use with phosphodiesterase inhibitors (e.g. sildenafil) due to risk of severe hypotension

Adverse effects

• Headache
• Dizziness
• Hypotension
• Flushing
• Tachycardia
• Palpitations
• Nausea
• Vomiting

Interactions

• Nitrates may enhance the effects of other antihypertensive agents
• Use with caution with alcohol, as it may exacerbate hypotensive effects
• Interactions may occur with phosphodiesterase type 5 inhibitors (e.g. sildenafil) leading to severe hypotension

Precautions

• Caution in patients with recent myocardial infarction or congestive heart failure
• Use with caution in patients with hepatic or renal impairment
• Monitor blood pressure regularly during treatment
• Consider tolerance development with long-term use

Pregnancy

Limited data available on the use of mononitrate in pregnancy. It should only be used if clearly needed and the benefits outweigh the risks.

Breast-feeding

Limited data available. Consider the benefits of breastfeeding against the need for the medication.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Extended-release tablets
• Sustained-release capsules
• Oral tablets

Indications

• Dermatitis
• Acne
• Rosacea
• Hyperpigmentation
• Skin aging

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines for paediatric patients.

Adults: Refer to the BNF for specific dosing guidelines based on the condition being treated.

Mechanism of action

Niacinamide functions primarily as a precursor to NAD and NADP, which are crucial for numerous enzymatic reactions in the body. It is involved in the NAD salvage pathway, which recycles nicotinamide for NAD synthesis. This process is vital for cellular energy production and metabolic processes. Niacinamide also has anti-inflammatory properties, which may contribute to its effects in skin health.

Pharmacodynamics

Niacinamide exhibits various pharmacological effects, including enhancing skin barrier function, reducing inflammation, and improving skin pigmentation. It has been shown to modulate keratinocyte function, improve collagen synthesis, and decrease the synthesis of sebum, thereby providing beneficial effects in conditions like acne and rosacea.

Pharmacokinetics

Niacinamide is readily absorbed from the gastrointestinal tract. It is distributed widely throughout the body and can cross biological membranes. The metabolism of niacinamide primarily occurs in the liver through methylation and conjugation, and it is excreted in urine as metabolites. The half-life of niacinamide is approximately 1-2 hours, and its effects can be prolonged due to its role in NAD synthesis.

Pregnancy

No evidence of harm, but use only if clearly needed.

Breast-feeding

Considered safe to use while breastfeeding.

Storage

Store in a cool, dry place away from light.

Formulations

• {'type': 'Topical cream', 'concentration': 'Various concentrations available'}
• {'type': 'Oral tablets', 'concentration': '100 mg, 250 mg, 500 mg'}

Indications

• Vitamin deficiency syndromes
• Malnutrition
• Support during pregnancy and lactation
• Immune system support
• Antioxidant therapy

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing recommendations, as they vary widely depending on the vitamin and the child's age and health status.

Adults: Refer to specific vitamin preparations and their recommended dosages as per BNF guidelines; dosing varies based on the type of vitamin and clinical context.

Mechanism of action

Vitamins perform diverse biological functions, acting as coenzymes or precursors for coenzymes in metabolic pathways. For example, B vitamins are integral in energy metabolism, while vitamins A, C, D, E, and K have roles in vision, immune function, antioxidant activity, and coagulation, respectively. Each vitamin interacts with specific enzymes and receptors to facilitate biochemical reactions essential for cellular function.

Pharmacodynamics

Vitamins are involved in various physiological processes, including but not limited to antioxidant protection, promotion of tissue healing, modulation of immune responses, regulation of gene expression, and maintenance of cellular integrity. Their effects can vary based on the specific vitamin, dosage, and individual patient factors, such as age, health status, and existing nutritional deficiencies.

Pharmacokinetics

The absorption of vitamins varies; fat-soluble vitamins (A, D, E, K) are absorbed along with dietary fats, while water-soluble vitamins (B-complex and C) are absorbed directly into the bloodstream. Factors influencing absorption include gastrointestinal health, the presence of other nutrients, and the formulation of the vitamin preparation. Once absorbed, vitamins are distributed throughout the body, with fat-soluble vitamins stored in liver and adipose tissues, while water-soluble vitamins are often excreted via urine when in excess.

Interactions

• tretinoin+vitamin: Severe (increases risk of vitaminatoxicity)
• retinoids+vitamin: Severe (increases risk of vitaminatoxicity)
• retinoids+vitamin: Moderate (increases risk of toxicity)
• carbamazepine+vitamin: Unknown (decreases effects)
• cobicistat+vitamin: Unknown (increases exposure)
• vitamindsubstances+digoxin: Unknown (increases risk of toxicity)
• idelalisib+vitamin: Unknown (increases exposure)
• clarithromycin+vitamin: Unknown (increases exposure)